- ‘Pocket drones’: U.S. Army developing tiny surveillance tools for the next big war
- Belgian cafe posts sign: Dogs allowed, but Jews stay out
- Gen. Dempsey: Pentagon studying Russian readiness plans not viewed ‘for 20 years’
- John McCain: Botched, two-hour execution of murderer is ‘torture’
- House GOP ready to move border bill
- Bomb squad called after live WWII artillery washes on Cape Cod beach
- HAYDEN: Intelligence, evidence and the case against Russia
- Ohio university quiz implies atheists are naturally smarter than Christians
- Rep. Henry Cuellar on border crisis: ‘Playing defense on the one-yard line’
- Activists vow to occupy fast-food restaurants to get higher pay
FDA reconsiders heart safety of common pain pills
Question of the Day
WASHINGTON (AP) - Federal health experts are taking a second look this week at the heart safety of pain medications used by millions of Americans to treat arthritis and other everyday aches and pains.
The Food and Drug Administration on Monday began a two-day meeting to examine the latest research on anti-inflammatory medicines called NSAIDS, which serve as the backbone of U.S. pain treatment.
The key question is whether naproxen - the key ingredient in Bayer’s Aleve and many other generic pain pills - carries a lower risk of heart attack and stroke than rival medications like ibuprofen, sold as Advil by Pfizer and Motrin by Johnson & Johnson, among others.
Debate about whether one drug is safer than others in the class has waged for more than a decade without a clear answer, underscoring the lingering questions that hang over even the most established medicines.
The FDA is asking its panel of medical experts to review a massive analysis published last year suggesting that naproxen does not increase the risk of heart problems as much as its peers. The finding came from Oxford University researchers who reviewed results from more than 700 NSAID studies involving roughly 350,000 patients.
On Tuesday panelists will vote on whether naproxen has a lower risk of heart problems than other NSAIDs. Panelists will also discuss whether naproxen should be relabeled based on the latest safety data. The FDA is not required to follow the group’s advice, though it often does.
If implemented, the labeling change could reshape the multibillion-dollar market for drugs used to treat muscle pain, arthritis and headaches. Last year U.S. consumers bought more than 275 million boxes of over-the-counter ibuprofen and naproxen, representing $1.7 billion in sales, according to retail tracker IRI. Prescription NSAIDs brought in billions more, led by the Pfizer’s blockbuster Celebrex, with sales of $2.9 billion.
But before any changes can be made, FDA advisers will have to wrestle with reams of data that are often riddled with complicating factors:
- The Oxford analysis is difficult to interpret because it combines information from hundreds of unrelated studies. While this approach is useful in getting a broad view of rare events - such as heart attacks - it is not considered the strongest form of medical evidence.
- Almost all of the data under discussion come from studies of prescription NSAID pain relievers, which are taken at higher doses and for longer periods than over-the-counter NSAIDs. But panelists will be asked to make recommendations on the use of non-prescription drugs as well.
Monday’s meeting mainly consisted of presentations dissecting the latest findings from academics, FDA scientists and drug company staffers.
The pharmaceutical companies generally staked out positions that would most benefit their respective products.
Bayer, which markets Aleve, said the drug’s labeling should reflect the new research suggesting it is a safer option.
Pfizer, maker of Advil and Celebrex, argued that there is no conclusive data that naproxen is safer than other products. The New York company said current labeling should remain in place until more conclusive evidence is available.
Pfizer is wrapping up work on a large multiyear study called PRECISION designed to definitely answer whether there is a difference in cardiovascular safety between naproxen, ibuprofen and Celebrex.
TWT Video Picks
Second- and third-stringers eye 2016 if front-runner stumbles
- 'We're coming for you, Barack Obama': Top U.S. official discloses threat from ISIL terrorists
- Russia shipping sophisticated weapons systems to Ukraine separatists
- NAPOLITANO: What if our democracy is a fraud?
- John McCain: Botched, two-hour execution of murderer is 'torture'
- Michelle Obama says money in politics is bad, asks donors for 'big, fat check'
- EDITORIAL: Detroit's water 'spigot bigots'
- Brian Kelly, Notre Dame ready for different route to title
- Ted Nugent loses second casino gig for 'racist remarks'
- Obama orders Pentagon advisers to Ukraine
- White House readies for House GOP impeachment push: 'Foolish' to ignore
Obama's biggest White House 'fails'
Celebrities turned politicians
Athletes turned actors
20 gadgets that changed the world
Fighting in Iraq